|
In vitro susceptibility of clinical isolates of
Aspergillusfimigatus to conventional and lipid
formulations of amphotericin B in 2-drug
combination with caspofimgin and micafungin
(click for details) |
|
|
|
Opportunistic infections of the respiratory system in
adults patients with HIV/AIDS
(click for details) |
|
|
|
Antifungal activity of voriconazole alone and in twodrug
combination with amphotericin B in a guinea pig
pulmonary aspergillosis model (click for details) |
|
|
|
Comparison of Aspergillus nidulans and Aspergillus
fumigatus as causes of osteomyelitis in patients with
chronic granulomatous disease (click for details) |
|
|
|
Infectious morbidity after non myeloablative
allogeneic bematopoietic stem cell transplantation
(AHSCT) (click for details) |
|
|
|
Antifungal efficacy, pharmacokinetics and
pharmacodynamics of intravenous itraconazole
against invasive pulmonary aspergillosis in persistently
neutropenic rabbits (click for details) |
|
|
|
Infections in hematopietic stem cell transplant (HSCT)
recipients (RC): 1994-2001 (click for details) |
|
|
|
New paradigms for the treatment of aspergillosis: polyenes (click for details) |
|
|
|
Interleukin-15 (IL-15) enhances the release of
interleukin-8 (IL-Q, but not of tumor necrosis factoralpha
(TNF-alpha) from unstimulated
polymorphonuclear leukocytes and following
challenge by Aspergillus species (click for details) |
|
|
|
Multicenter randomized trial of intra venous/oral
itraconazole vs. intra venous/oral fluconazole for
long-term antifungal prophylaxis in allogeneic
bone marrow transplant patients (click for details) |
|
|
